NCT02596997No Longer Available不适用
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Chimerix
- 试验地点
- 46
研究概览
简要总结
Provide patients with serious AdV infection or disease access to treatment with BCV.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 2 Months 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed serious AdV infection based on clinical symptoms and laboratory testing showing AdV in the blood or other bodily fluids
- •Able to swallow medication, either tablet or liquid
排除标准
- •Previous dosing with Brincidofovir
- •If female, not pregnant or trying to become pregnant
研究者
研究点 (46)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisALSLou Gehrig DiseaseLou Gehrig's DiseaseLou-Gehrigs DiseaseMotor Neuron Disease, Amyotrophic Lateral SclerosisNCT03537807Biohaven Pharmaceuticals, Inc.
Available
不适用
Expanded Access to Ensartinib for Participants With ALK+ NSCLCALK Gene Rearrangement PositiveNon-Small Cell Lung CancerNCT04146571Xcovery Holdings, Inc.
Approved For Marketing
不适用
Intermediate-Size Patient Population Expanded Access Program for Intravenous DifelikefalinUremic PruritusNCT05031546Cara Therapeutics, Inc.
No Longer Available
不适用
Expanded Access for PSV Personalized Oncolytic VirusesCancerNCT03529539EpicentRx, Inc.
Unknown
不适用
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 SyndromePost COVID-19 SyndromeNCT04798066Hope Biosciences Research Foundation